
	ImmunoGen, Inc. develops targeted anticancer therapeutics using our expertise in cancer biology, engineered antibodies and highly potent cancer-cell killing agents. We have established expertise in the development and humanization of tumor-targeting antibodies. As is well accepted, engineered antibodies can do an excellent job of selectively binding to cancer cells, but are typically sub-optimal in their ability to actually kill cancer cells. Thus, we have developed specialized cancer-cell killing agents to serve as payloads &ndash; to be attached to such antibodies for targeted delivery to tumor cells.
